Loading
Surgical stress releases catecholamines and prostaglandins that suppress anti-tumour immunity and help metastatic cells seed. Phase 2 trials of a five-day course of propranolol plus etodolac around breast and colorectal surgery shifted tumour markers of metastasis and immune suppression in the right direction; both drugs cost cents, and a publicly funded phase 3 is the missing step.
Surgical stress releases catecholamines and prostaglandins that suppress anti-tumour immunity and promote metastatic seeding in animal models. Phase 2 trials of propranolol plus etodolac around surgery in breast and colorectal cancer (Ben-Eliyahu and colleagues) showed favourable changes in tumour transcriptomic markers of metastasis and immune suppression, and a small colorectal trial suggested reduced recurrence. Both drugs cost cents. The proposal is a publicly funded, multinational phase 3 in colorectal and breast cancer with disease-free survival as the primary endpoint.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares Metastasis is understood least and studied last, No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.